Head-to-head · free

Nuwellis, Inc. vs PDS Biotechnology Corporation

NUWE vs PDSB — return on capital, cash generation, margins and balance sheet side by side.

NUWE

2 / 4

measures where NUWE leads

PDSB

2 / 4

measures where PDSB leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureNUWE · FY2025PDSB · FY2025
Revenue$8.3M—
Net income(17.5M)(8.5M)
Revenue growth (yearly, multi-year)1.1%—
Free cash flow(10.9M)(27.8M)
Free cash flow margin-131.8%—
Net cash / (debt)——
ROIC——
Return on equity-382.8%-244.2%
Gross margin62.0%—
Operating margin-134.3%—
Net debt / EBITDA0.10x0.31x

Figures are as reported by each company; latest fiscal year shown.

Where Nuwellis, Inc.'s cash went (FY2025)

Capital spending
$90000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full NUWE profile →

Where PDS Biotechnology Corporation's cash went (FY2025)

Capital spending
$0
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full PDSB profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons